New strategies in composite tissue allotransplantation

Gerald Brandacher, Maria Chicco, W. P. Andrew Lee

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the last two decades, composite tissue allotransplantation (CTA), more recently referred to as vascularized composite allotransplantation (VCA), has become a valid therapeutic and restorative option for patients with severe tissue defects. While functional outcomes are such that recipients' quality of life is significantly improved and in some cases even dramatically enhanced, long-term risks are still difficult to evaluate in a precise fashion. Strategies have been devised, and new ones are being explored, in order to minimize or, if possible, eliminate the need for immunosuppression while keeping rejection under control. Success in these efforts would ultimately tilt the risk versus benefit balance, so that VCA may become widely adopted and a standard therapeutic option. This chapter introduces a brief historical perspective as well as a description of the current state of play within the discipline. It examines emerging challenges and then focuses on novel research avenues and clinical perspectives for the future.

Original languageEnglish (US)
Title of host publicationTechnological Advances in Organ Transplantation
PublisherSpringer International Publishing
Pages215-234
Number of pages20
ISBN (Electronic)9783319621425
ISBN (Print)9783319621418
DOIs
StatePublished - May 23 2018
Externally publishedYes

Fingerprint

Vascularized Composite Allotransplantation
Tissue
Composite materials
Immunosuppression
Quality of Life
Defects
Therapeutics
Research

ASJC Scopus subject areas

  • Medicine(all)
  • Health Professions(all)
  • Engineering(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Brandacher, G., Chicco, M., & Andrew Lee, W. P. (2018). New strategies in composite tissue allotransplantation. In Technological Advances in Organ Transplantation (pp. 215-234). Springer International Publishing. https://doi.org/10.1007/978-3-319-62142-5_9

New strategies in composite tissue allotransplantation. / Brandacher, Gerald; Chicco, Maria; Andrew Lee, W. P.

Technological Advances in Organ Transplantation. Springer International Publishing, 2018. p. 215-234.

Research output: Chapter in Book/Report/Conference proceedingChapter

Brandacher, G, Chicco, M & Andrew Lee, WP 2018, New strategies in composite tissue allotransplantation. in Technological Advances in Organ Transplantation. Springer International Publishing, pp. 215-234. https://doi.org/10.1007/978-3-319-62142-5_9
Brandacher G, Chicco M, Andrew Lee WP. New strategies in composite tissue allotransplantation. In Technological Advances in Organ Transplantation. Springer International Publishing. 2018. p. 215-234 https://doi.org/10.1007/978-3-319-62142-5_9
Brandacher, Gerald ; Chicco, Maria ; Andrew Lee, W. P. / New strategies in composite tissue allotransplantation. Technological Advances in Organ Transplantation. Springer International Publishing, 2018. pp. 215-234
@inbook{3dbf983d269c4289961b6bb853c25a7d,
title = "New strategies in composite tissue allotransplantation",
abstract = "Over the last two decades, composite tissue allotransplantation (CTA), more recently referred to as vascularized composite allotransplantation (VCA), has become a valid therapeutic and restorative option for patients with severe tissue defects. While functional outcomes are such that recipients' quality of life is significantly improved and in some cases even dramatically enhanced, long-term risks are still difficult to evaluate in a precise fashion. Strategies have been devised, and new ones are being explored, in order to minimize or, if possible, eliminate the need for immunosuppression while keeping rejection under control. Success in these efforts would ultimately tilt the risk versus benefit balance, so that VCA may become widely adopted and a standard therapeutic option. This chapter introduces a brief historical perspective as well as a description of the current state of play within the discipline. It examines emerging challenges and then focuses on novel research avenues and clinical perspectives for the future.",
author = "Gerald Brandacher and Maria Chicco and {Andrew Lee}, {W. P.}",
year = "2018",
month = "5",
day = "23",
doi = "10.1007/978-3-319-62142-5_9",
language = "English (US)",
isbn = "9783319621418",
pages = "215--234",
booktitle = "Technological Advances in Organ Transplantation",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - New strategies in composite tissue allotransplantation

AU - Brandacher, Gerald

AU - Chicco, Maria

AU - Andrew Lee, W. P.

PY - 2018/5/23

Y1 - 2018/5/23

N2 - Over the last two decades, composite tissue allotransplantation (CTA), more recently referred to as vascularized composite allotransplantation (VCA), has become a valid therapeutic and restorative option for patients with severe tissue defects. While functional outcomes are such that recipients' quality of life is significantly improved and in some cases even dramatically enhanced, long-term risks are still difficult to evaluate in a precise fashion. Strategies have been devised, and new ones are being explored, in order to minimize or, if possible, eliminate the need for immunosuppression while keeping rejection under control. Success in these efforts would ultimately tilt the risk versus benefit balance, so that VCA may become widely adopted and a standard therapeutic option. This chapter introduces a brief historical perspective as well as a description of the current state of play within the discipline. It examines emerging challenges and then focuses on novel research avenues and clinical perspectives for the future.

AB - Over the last two decades, composite tissue allotransplantation (CTA), more recently referred to as vascularized composite allotransplantation (VCA), has become a valid therapeutic and restorative option for patients with severe tissue defects. While functional outcomes are such that recipients' quality of life is significantly improved and in some cases even dramatically enhanced, long-term risks are still difficult to evaluate in a precise fashion. Strategies have been devised, and new ones are being explored, in order to minimize or, if possible, eliminate the need for immunosuppression while keeping rejection under control. Success in these efforts would ultimately tilt the risk versus benefit balance, so that VCA may become widely adopted and a standard therapeutic option. This chapter introduces a brief historical perspective as well as a description of the current state of play within the discipline. It examines emerging challenges and then focuses on novel research avenues and clinical perspectives for the future.

UR - http://www.scopus.com/inward/record.url?scp=85053364236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053364236&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-62142-5_9

DO - 10.1007/978-3-319-62142-5_9

M3 - Chapter

AN - SCOPUS:85053364236

SN - 9783319621418

SP - 215

EP - 234

BT - Technological Advances in Organ Transplantation

PB - Springer International Publishing

ER -